Marine Microbial Fibrinolytic Enzymes: An Overview of Source, Production, Biochemical Properties and Thrombolytic Activity

Mar Drugs. 2022 Jan 2;20(1):46. doi: 10.3390/md20010046.

Abstract

Cardiovascular diseases (CVDs) have emerged as a major threat to global health resulting in a decrease in life expectancy with respect to humans. Thrombosis is one of the foremost causes of CVDs, and it is characterized by the unwanted formation of fibrin clots. Recently, microbial fibrinolytic enzymes due to their specific features have gained much more attention than conventional thrombolytic agents for the treatment of thrombosis. Marine microorganisms including bacteria and microalgae have the significant ability to produce fibrinolytic enzymes with improved pharmacological properties and lesser side effects and, hence, are considered as prospective candidates for large scale production of these enzymes. There are no studies that have evaluated the fibrinolytic potential of marine fungal-derived enzymes. The current review presents an outline regarding isolation sources, production, features, and thrombolytic potential of fibrinolytic biocatalysts from marine microorganisms identified so far.

Keywords: cardiovascular diseases; fibrinolytic enzymes; marine microorganisms; thrombolytic activity.

Publication types

  • Review

MeSH terms

  • Animals
  • Aquatic Organisms
  • Bacteria*
  • Fibrinolysis / drug effects*
  • Fibrinolytic Agents / chemistry
  • Fibrinolytic Agents / pharmacology*
  • Fibrinolytic Agents / therapeutic use
  • Microalgae*
  • Thrombosis / drug therapy*

Substances

  • Fibrinolytic Agents